Concepedia
Statistics
Publications
6
Citations
152
H-Index
Active since
2018
Affiliations
The Netherlands Cancer Institute(Current)
University of Groningen
University Medical Center Utrecht
University Medical Center Groningen
Erasmus MC Cancer Institute
M. Jebbink is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and targeted cancer therapy.
Publications per year
2018–2023
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
Adrianus J. de Langen, M. Jebbink, Sayed M.S. Hashemi et al. · British Journal of Cancer · 2018 · 45 citations · Full text
Medicine, Oncology, Pharmacology +17
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
Jade M. van Berge Henegouwen, M. Jebbink, Louisa R. Hoes et al. · European Journal of Cancer · 2022 · 27 citations · Full text
Medicine, Oncology, Pharmacology +16
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response
Floris Dammeijer, Cornedine J. de Gooijer, Mandy van Gulijk et al. · EBioMedicine · 2021 · 26 citations · Full text
Medicine, Immunology, Oncology +17
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
M. Jebbink, Adrianus J. de Langen, Kim Monkhorst et al. · JTO Clinical and Research Reports · 2023 · 22 citations · Full text
Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting
René J. Boosman, M. Jebbink, Wouter B. Veldhuis et al. · Pharmaceutical Research · 2022 · 21 citations · Full text
Medicine, Oncology, Pharmacology +13
1–5 of 6